Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 14/20 | 0.52 |
| ▸ | ALOX5 | P09917 | 10/20 | 0.52 |
| ▸ | PTGES | O14684 | 9/20 | 0.52 |
| ▸ | PPARA | Q07869 | 8/20 | 0.52 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.51 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.51 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9318904 | 0.88 | PPARG (0.49) | PPARGALOX5PTGESPPARAPLA2G4B | |
| SCHEMBL4265985 | 0.79 | PPARG (0.62) | PPARGALOX5PTGESPPARA | |
| SCHEMBL9318980 | 0.77 | PPARG (0.45) | PPARGALOX5PTGESPPARACYSLTR2 | |
| SCHEMBL9318310 | 0.77 | CYSLTR2 (0.51) | PPARGALOX5PTGESPPARACYSLTR2 | |
| SCHEMBL9359601 | 0.77 | NPSR1 (0.63) | CYSLTR2CYSLTR1PLA2G4BALDH1A1NPSR1 | |
| SCHEMBL7073696 | 0.76 | PPARG (0.50) | PPARGALOX5PTGESPPARA | |
| SCHEMBL14155870 | 0.75 | PPARG (0.44) | PPARGALOX5PTGESPPARA | |
| SCHEMBL9319494 | 0.74 | CYSLTR2 (0.48) | PPARGPPARACYSLTR2CYSLTR1PLA2G4B | |
| SCHEMBL7511090 | 0.74 | MMP9 (0.48) | PPARGALOX5PTGES | |
| SCHEMBL9099026 | 0.74 | PPARG (0.64) | PPARGALOX5PTGESPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0576603-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PROSTATIC HYPERPLASIA, CONTAINING A 5 ALPHA-REDUCTASE INHIBITOR AND AN ANTIANDROGEN | MERCK & CO. INC. (US) | 1994-01-05 | — | — | EP | disclosed |